The COVID-19 pandemic magnified the inequities in public health across the globe. Learning from experiences, policymakers across the world have rightly endorsed the need to improve the global health architecture as a tool to catalyse economic growth and secure the future of the planet. Greater health financing through international collaborations, deepening the adoption of digital health solutions, and increasing access to medical countermeasures are some of the aspects that are key to reducing the global disparity in health and strengthening the global health architecture. However, amidst these crucial strategies, prioritising access to blood and its products remains fundamental to building a resilient global health architecture.
Blood and its various products play a crucial role in a number of medical scenarios, which includes scheduled surgeries, emergency procedures, as well as in the treatment of conditions such as cancer, thalassemia, and postpartum haemorrhage (PPH). This underscores their irreplaceable significance in upholding patient health across a spectrum of health-care needs.
